featured
Zanubrutinib, Obinutuzumab, and Venetoclax as a First-Line Treatment for TP53-Mutant Mantle Cell Lymphoma
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
Blood
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Zanubrutinib, Obinutuzumab, and Venetoclax for First-Line Treatment of Mantle Cell Lymphoma with a TP53 Mutation
Blood 2024 Oct 22;[EPub Ahead of Print], A Kumar, JD Soumerai, JS Abramson, JA Barnes, PC Caron, S Chhabra, M Chabowska, A Dogan, L Falchi, C Grieve, JE Haydu, PC Johnson, A Joseph, H Kelly, A Labarre, JK Lue, R Martignetti, J Mi, AJ Moskowitz, CN Owens, S Plummer, M Puccio, GA Salles, VE Seshan, E Simkins, N Slupe, H Zhang, AD ZelenetzFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.